Zevra Therapeutics (ZVRA, Financial) has officially submitted its definitive proxy statement to the U.S. Securities and Exchange Commission ahead of its 2025 Annual Meeting of Stockholders, scheduled for May 29. Shareholders recorded as of April 4 will be eligible to vote at this meeting.
The Zevra Board of Directors is urging stockholders to support the re-election of two key directors, Wendy L. Dixon, Ph.D., and Tamara A. Favorito, using the WHITE proxy card. Both directors bring significant expertise in public company oversight and life sciences management, which has been instrumental in advancing Zevra's strategic objectives. Their experience is seen as vital to maintaining the momentum the company has achieved.
In parallel with the proxy filing, Zevra is dispatching a letter to shareholders highlighting its transformative journey over the past two years into a more robust, growth-oriented entity. This communication also addresses an attempt by shareholder Daniel J. Mangless to replace the current directors with his nominees, a move that the company believes could hinder its ongoing progress and compromise long-term value creation.
Zevra underscores its refreshed Board and management's effectiveness, citing the successful launch of two rare disease therapies and an enhanced commercial portfolio. With seven of the current eight directors joining since 2023, the company believes its leadership is well-equipped to steer its continued growth. The Board’s nominees are credited with driving significant improvements and are deemed essential for the governance of Zevra as it continues to expand its commercial-stage rare disease operations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Zevra Therapeutics Inc (ZVRA, Financial) is $22.29 with a high estimate of $25.00 and a low estimate of $18.00. The average target implies an upside of 211.69% from the current price of $7.15. More detailed estimate data can be found on the Zevra Therapeutics Inc (ZVRA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Zevra Therapeutics Inc's (ZVRA, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Zevra Therapeutics Inc (ZVRA, Financial) in one year is $25.22, suggesting a upside of 252.73% from the current price of $7.15. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Zevra Therapeutics Inc (ZVRA) Summary page.
